164 related articles for article (PubMed ID: 36503588)
1. Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study.
Nishita Y; Taga M; Sakurai M; Iinuma Y; Masauji T
J Pharm Health Care Sci; 2022 Dec; 8(1):32. PubMed ID: 36503588
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation.
Eguchi Y; Gando S; Ishikura H; Saitoh D; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Matsushita T; Tsujita R; Nagao O; Sakata Y
J Intensive Care; 2014; 2(1):30. PubMed ID: 25520842
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.
Imaura M; Tsumori M; Nagase S; Omura K; Takahashi H; Hatoyama-Tanaka S; Katagiri F; Takayanagi R; Kanno H; Yamada Y
Shock; 2020 Jul; 54(1):50-55. PubMed ID: 31764622
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
[TBL] [Abstract][Full Text] [Related]
6. The effect of recombinant human soluble thrombomodulin on renal function and mortality in septic disseminated intravascular coagulation patients with acute kidney injury: a retrospective study.
Akatsuka M; Masuda Y; Tatsumi H; Sonoda T
J Intensive Care; 2020 Dec; 8(1):94. PubMed ID: 33308326
[TBL] [Abstract][Full Text] [Related]
7. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
[TBL] [Abstract][Full Text] [Related]
8. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
[TBL] [Abstract][Full Text] [Related]
10. Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.
Nakano K; Sugiyama K; Satoh H; Arifuku H; Fujimatsu T; Yoshida N; Watanabe H; Tokita S; Wakayama T; Tatewaki M; Souma R; Masuda H; Koyama K; Hirata H; Fukushima Y
Intern Med; 2017; 56(14):1799-1806. PubMed ID: 28717074
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
[TBL] [Abstract][Full Text] [Related]
12. Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery.
Konishi H; Okamoto K; Shoda K; Arita T; Kosuga T; Morimura R; Komatsu S; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Otsuji E
World J Gastroenterol; 2017 Feb; 23(5):891-898. PubMed ID: 28223734
[TBL] [Abstract][Full Text] [Related]
13. Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation.
Kimpara N; Tawara S; Kawasaki K
Thromb Res; 2019 Jul; 179():73-80. PubMed ID: 31096113
[TBL] [Abstract][Full Text] [Related]
14. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
[TBL] [Abstract][Full Text] [Related]
15. OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION.
Imaura M; Katagiri F; Nagase S; Hatoyama-Tanaka S; Takahashi H; Takayanagi R; Kanno H; Yamada Y
Shock; 2023 Aug; 60(2):221-226. PubMed ID: 37342874
[TBL] [Abstract][Full Text] [Related]
16. Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation.
Iba T; Hagiwara A; Saitoh D; Anan H; Ueki Y; Sato K; Gando S
Ann Intensive Care; 2017 Nov; 7(1):110. PubMed ID: 29098447
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
[TBL] [Abstract][Full Text] [Related]
18. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study.
Kato T; Matsuura K
Thromb J; 2018; 16():19. PubMed ID: 30158838
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation.
Takeuchi M; Tanoshima R; Miyagawa N; Sarashina T; Kato H; Kajiwara R; Ito S; Goto H
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27734584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
